News

Applied Clinical Trials Online17h
Alexion’s Dual-Binding Nanobody Demonstrates Statistically Significant Improvements in Generalized Myasthenia Gravis
Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...
Applied Clinical Trials Online21h
FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors
Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.